Measured in a cell proliferation assay using HUVEC cells,the EC50 for this effect is less than 2ng/ml.
Product Details
Product Details
Product Specification
Species | Human |
Antigen | VEGF-121 |
Synonyms | Vascular Endothelial Growth Factor-A, VEGFA |
Accession | P15692-9 |
Amino Acid Sequence | Ala27-Arg147 |
Expression System | E.coli |
Molecular Weight | 14kDa |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | 20mM PB, 150mM NaCl, pH 7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | 1.FASEB J. 2001 Jul;15(9):1667-9. |
Background
VEGF-121, an abundant splicing isoform of vascular endothelial growth factor (VEGF), exists as a disulfide-linked homodimer. It induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Contrast to other isoforms, VEGF-121 has very little affinity for heparin-sulfate proteoglycans, without recruiting Neuropilin1-expressing monocytes (NEMs), conferring to VEGF-121 the ability to diffuse freely, and increase tumor growth rate in vivo.
Picture
Picture
Bioactivity


Immobilized VEGF-121, Human (Cat. No. UA040082) at 0.5μg/mL (100μL/well) can bind Bevacizumab (starter-bio, Cat. No. S0B0437) with EC50 of 1.20-1.54 ng/mL.
SDS-PAGE

1μg (R: reducing condition, N: non-reducing condition).
ELISA

Immobilized VEGF-121, Human (Cat. No. UA040082) at 2.0μg/mL (100μL/well) can bind VEGF-R2/KDR Fc Chimera, Human (Cat. No. UA010144) with EC50 of 8.25-11.55 ng/mL.



